Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company to Feature Type 2 Diabetes Research in More Than 25 Presentations at the 71st American Diabetes Association Scientific Sessions
RIDGEFIELD, Conn. and INDIANAPOLIS, June 20, 2011 /PRNewswire/ -- Boehringer Ingelheim and Eli Lilly and Company(NYSE: LLY) will present the latest data from their diabetes portfolio at the 71st American Diabetes Association (ADA) Scientific Sessions in San Diego on June 24-28. Study results evaluating the dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin, as well as the investigational sodium glucose cotransporter2 (SGLT2) inhibitor BI-10773, will be featured among the 27 presentations. Linagliptin, 5 mg, is marketed under the trade name Tradjenta (linagliptin) tablets in the U.S. and was approved by the U.S. Food and Drug Administration (FDA) in May 2011 to be used along with diet and exercise to lower blood sugar in adults with type 2 diabetes. TRADJENTA should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis (increased ketones in the blood or urine). It has not been studied in combination with insulin.
To view the multimedia assets associated with this release, please click: http://multivu.prnewswire.com/mnr/boehringer-ingelheim/50750/
Two linagliptin abstracts were selected by ADA as President's Posters, a prestigious session showcasing 100 specially-selected posters on Sunday, June 26 and repeated on Monday, June 27. Two additional Phase III studies evaluating cardiovascular events will be highlighted as late-breaking posters.